Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Summary
Third Opinion Trial Synopsis:
This study is trying to see if a medicine called leflunomide can help African-American and European-American patients with a type of cancer called high-risk smoldering multiple myeloma. Leflunomide can make our body's immune response weaker and may help delay the symptoms of multiple myeloma.
This study is trying to see if a medicine called leflunomide can help African-American and European-American patients with a type of cancer called high-risk smoldering multiple myeloma. Leflunomide can make our body's immune response weaker and may help delay the symptoms of multiple myeloma.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: